1
Sustainable Profitable Growth through Innovation Pascal Soriot Chief Operating Officer Roche Pharmaceuticals 2
Q1 2009: A good start into the year 3
Q1 2010: High growth for both divisions Well above world markets CHF bn % change in Q1 09 Q1 10 CHF local Pharmaceuticals 9.2 9.7 6 10 Diagnostics 2.4 2.5 7 9 Roche Group 11.6 12.2 6 9 4
Roche: Biotech products drive growth 47% Biologics as proportion of Pharma sales 67% Leader in Biotech 67% of Pharma sales from biotech products Approx. 85% of Diagnostics sales from biotech products Least patent exposure of all major biotech/pharma companies Q1 2005 Q1 2010 Biologics 5
Q1 2010: Oncology late-stage pipeline update T-DM1 in advanced breast cancer Single-agent, phase II data in patients pre-treated with Herceptin, lapatinib and chemotherapy After successful discussion with FDA: To be filed 2010 T-DM1 target patient population HER2+ Rx Opportunities US 5 EU 2L 6,100 8,300 3L 4,400 3,750 4L 3,200 1,700 Avastin in first-line ovarian cancer 5 cycles of paclitaxel and carboplatin +Avastin, followed by Avastin maintenance for up to 22 cycles To be filed 2010 Unprecedented efficacy in heavily pretreated HER2+ mbc 33% ORR Single agent data indicates better tolerability than standard chemotherapycontaining regimens 6
Actemra/RoActemra launch on track CHF m 70 60 50 40 30 Rollout in additional countries Successful start in the US Uptake in Japan remains strong Used as first-line biologic in countries where indication is approved Clinical program to support further growth 20 10 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2008 2008 2008 2008 2009 2009 2009 20092010 FUNCTION: Phase III Early RA patients - Ongoing ACTEMRA vs HUMIRA FPI planned 2010 Subcutaneous ACTEMRA FPI planned 2010 7
What makes Roche unique? 8
Medical breakthroughs have always driven our business Roche Sales Monoclonal antibodies e.g. MabThera, Avastin Anti-bacterials e.g. Rocephin PCR Vitamin synthesis e.g. Vitamin C Benzodiazepines e.g. Valium 1896 1930 1960 1980 1990 2000 2009 9
Roche: Focused on medically differentiated therapies Value Focus Pharma Dia MedTech OTC Generics Differentiation 10
Late-stage pipeline continues to build up Expanding into new therapeutic areas Number of NMEs Virology CNS Metabolic Inflammation Oncology 10 GlyT-1 inh aleglitazar taspoglutide dalcetrapib up to 13 HCV pol inh * ocrelizumab MS* GlyT-1 inh SGLT2 inh* aleglitazar taspoglutide dalcetrapib 4 ocrelizumab Hedgehog inh lebrikizumab * Hedgehog inh 2 taspoglutide dalcetrapib BRAF inhibitor T-DM1 BRAF inhibitor T-DM1 ocrelizumab ocrelizumab RG7159 (CLL) RG7159 (CLL, NHL) Actemra pertuzumab pertuzumab pertuzumab 2007 2008 2009 2010E * LIP or phase III decision pending 11
Emerging markets also reward innovation Roche has the leading growth rate in emerging markets % Market Share Full Year 2009 YoY Growth % 3.7% ROCHE 13.2 5.3% 3.1% 3.2% 5.4% NOVARTIS ASTRAZENECA BAYER SANOFI-AVENTIS 11.5 10.3 9.7 8.9 3.5% 5.4% GSK PFIZER 6.4 7.2 3.6% MERCK & CO 6.1 0 5 10 15 Source: IMS Health MIDAS FY 2009 US$ LC Roche International Regions: Asia Pac, CEMAI, Lat AM (based on Roche subscription) 12
How much money to invest in R&D? 13
Majority of R&D investment goes into product development Split of R&D costs for Pharma (Roche and Genentech) CHF 8.0 billion in 2009* research & preclinical phase I, II and III phase IV More than 70 % of our R&D investments go into product development * Excluding Chugai and one-off impairments of intangible assets 14
Strong late-stage portfolio of NMEs Limited risk due to rigorous proof of concept studies CHF 5 bn Peak sales CHF 2 bn dalcetrapib T-DM1 (early launch) aleglitazar ocrelizumab MS* GlyT-1 inh GA101 pertuzumab taspoglutide T-DM1 BRAF inh (Melanoma) Hedgehog inh (BCC) * Phase III go/no go decision pending 0% 50% 100% Probability of technical success 15
Roche: Uniquely positioned to deliver long-term growth Combination of biotech portfolio and strong pipeline Roche Pharmaceuticals sales Strong late-stage pipeline NMEs Illustrative Long patent protection of existing portfolio 35 line extensions could be filed by end 2014 Defendable base post patent expiries (biotech) Existing portfolio 2009 2020 16